Differentiated Thyroid Cancer (DTC) was the most diagnosed cancer in adolescents and young adults (AYA) aged 15-29 in Canada in 2023. In recent years, there has been an increasing awareness of the high prevalence of actionable oncogenic fusions in pediatric papillary thyroid cancer, including NTRK and RET fusions.
This study aims to better understand both the physical and psycho-social long-term effects of survivors diagnosed and treated for DTC in British Columbia (BC). Using the CAYACS cohort, we aim to build new evidence-based guidance on surveillance and advocacy for this subset of cancer survivors. Specific objectives are to: i) quantify and assess the development of secondary malignancies in DTC survivors in BC; ii) examine the healthcare utilization for CAYA DTC survivors; and iii) identify specific healthcare utilization for mental health concerns and antidepressant use of CAYA DTC survivors.
Principal Investigator: Rod Rassekh, BC Children’s Hospital; Rachel Altman, Simon Fraser University
Principal Investigator: Stuart Peacock, BC Cancer, Simon Fraser University
Principal Investigator: Stuart Peacock, BC Cancer, Simon Fraser University
Principal Investigator: Helen McTaggart-Cowan, BC Cancer, Simon Fraser University
Principal Investigators: Mary De Vera, University of British Columbia; Helen McTaggart-Cowan, BC Cancer and Simon Fraser University
Principal Investigator: Stuart Peacock, BC Cancer, Simon Fraser University
Principal Investigator: Meera Rayar, BC Children’s Hospital, University of British Columbia